News
Shire Receives Positive CHMP Opinion in Europe for Revestive for Paediatric Patients with Short Bowel Syndrome
Shire plc announced that the EMA Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the extension of the approval of Revestive®* (teduglutide) 5 mg powder and solvent for solution for injection in paediatric patients...
News
Amgen Receives Positive CHMP Opinion To Extend Indication Of Kyprolis® (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma
Amgen announced that theCommittee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion to extend the current indication for Kyprolis® (carfilzomib) to include treatment in combination with dexamethasone alone for adult...
News
Takeda Receives Positive CHMP Opinion for ADCETRIS as Consolidation Treatment in Post-Transplant Hodgkin Lymphoma
Takeda Pharmaceutical Company Limited announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the extension of the current conditional approval of ADCETRIS® (brentuximab vedotin) and recommended its...
News
Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Healthcare Conference
Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Ian Read, Chairman and CEO at the Bernstein 32nd Annual Strategic Decisions Conference on Thursday, June 2, 2016 at 2:00 p.m. Eastern...
News
AbbVie to Present at the Jefferies 2016 Healthcare Conference
AbbVie will participate in the Jefferies 2016 Healthcare Conference on Wednesday, June 8, 2016. Bill Chase, executive vice president and chief financial officer, will participate in a question and answer session at 7:30 a.m. Central time. ...
News
STELARA Induced Clinical Response And Remission In Phase 3 Study For The Treatment Of Patients With Moderate To Severe Crohn’s Disease
Janssen Research & Development, LLC (Janssen) Phase 3 data presented for the first time at Digestive Disease Week® 2016 showed that a significantly greater proportion of adult patients with moderate to severe Crohn's disease receiving STELARA®(ustekinumab) subcutaneous (SC) maintenance...
News
Novartis Entresto given strong Class I recommendation in both US and EU heart failure guidelines, less than a year after regulatory approvals
US guidelines now recommend Entresto as standard of care for HFrEF as an alternative to ACEs or ARBs; call for doctors to switch patients with mild to moderate symptoms to Entresto Updated guidelines from the European Society of...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
















